$MREO

Mereo BioPharma faces securities lawsuit alleging misrepresentations about Phase 3 trial results for setrusumab, causing investor losses.

Mereo BioPharma faces class action lawsuit over allegedly false statements regarding failed Phase 3 clinical trials. Investors who bought securities between June 2023-December 2025 may be eligible to participate.

Mereo BioPharma faces securities litigation alleging it misled investors about Phase 3 clinical trial results for setrusumab, failing to disclose the trials missed primary endpoints.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors who purchased shares between June 2023 and December 2025 may be eligible.

Mereo BioPharma faces securities lawsuit for allegedly making false statements about setrusumab trial results, causing artificially inflated stock prices and investor losses.

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors claim the company concealed negative trial results.